NEPH Stock Overview
A commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nephros, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.54 |
| 52 Week High | US$4.04 |
| 52 Week Low | US$1.36 |
| Beta | 1.19 |
| 1 Month Change | 1.99% |
| 3 Month Change | -13.48% |
| 1 Year Change | -50.16% |
| 3 Year Change | -74.33% |
| 5 Year Change | -84.81% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
It's A Story Of Risk Vs Reward With Nephros, Inc. (NASDAQ:NEPH)
Oct 03
We're Not Worried About Nephros' (NASDAQ:NEPH) Cash Burn
Jul 14Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Have Been Cutting Their Estimates
May 13After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar
Dec 18At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?
Dec 14Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation
Sep 28US$5.13: That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After Its Latest Results
Aug 13Market Sentiment Around Loss-Making Nephros, Inc. (NASDAQ:NEPH)
Mar 25At US$8.37, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?
Mar 04Announcing: Nephros (NASDAQ:NEPH) Stock Increased An Energizing 131% In The Last Five Years
Jan 28Nephros sees Q4 revenue in-line with estimates,
Jan 12Nephros, Inc. (NASDAQ:NEPH) Insiders Increased Their Holdings
Dec 08Nephros EPS beats by $0.02, misses on revenue
Nov 05Shareholder Returns
| NEPH | US Machinery | US Market | |
|---|---|---|---|
| 7D | -0.6% | -4.6% | -2.4% |
| 1Y | -50.2% | 12.3% | 23.4% |
Return vs Industry: NEPH underperformed the US Machinery industry which returned 12.3% over the past year.
Return vs Market: NEPH underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| NEPH volatility | |
|---|---|
| NEPH Average Weekly Movement | 5.3% |
| Machinery Industry Average Movement | 5.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NEPH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NEPH's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 31 | Robert Banks | www.nephros.com |
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment.
Nephros, Inc. Fundamentals Summary
| NEPH fundamental statistics | |
|---|---|
| Market cap | US$16.24m |
| Earnings (TTM) | -US$929.00k |
| Revenue (TTM) | US$13.55m |
1.2x
P/S Ratio-17.5x
P/E RatioIs NEPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEPH income statement (TTM) | |
|---|---|
| Revenue | US$13.55m |
| Cost of Revenue | US$5.28m |
| Gross Profit | US$8.27m |
| Other Expenses | US$9.20m |
| Earnings | -US$929.00k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.088 |
| Gross Margin | 61.04% |
| Net Profit Margin | -6.86% |
| Debt/Equity Ratio | 0% |
How did NEPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nephros, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Anthony Vendetti | Maxim Group |